TNPSC Thervupettagam

HIV-prevention drug CAB-LA

May 25 , 2023 394 days 342 0
  • The Indian drug company Cipla confirmed that a generic version of the prophylaxis, long-acting cabotegravir (CAB-LA), would be manufactured at its plants in Benoni, near Johannesburg, or Durban.
  • An affordable version of a HIV-prevention drug will be made in South Africa for the first time.
  • Cabotegravir blocks HIV from entering a person’s cells.
  • It reduces to almost zero an individual’s chances of getting infected with the virus through sex.
  • The developers of CAB-LA, ViiV Healthcare, and the UN-backed Medicines Patent Pool (MPP), had granted licences to three companies, including Cipla.
  • The other two companies, Aurobindo and Viatris, are also Indian corporations.

Leave a Reply

Your Comment is awaiting moderation.

Your email address will not be published. Required fields are marked *